ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1860

Novel Proinflammatory Microvesicles That Carry LL-37 In Patients With Cutaneous Lupus

Ming-Lin Liu1,2,3, Muhammad Bashir1,4, Meena Sharma1,4, Honghui Xu1,4, Kevin Williams3, Cynthia O. Anyanwu4,5, Joyce Okawa1,6 and Victoria P. Werth1,4, 1Department of Dermatology, University of Pennsylvania, Philadelphia, PA, 2Department of Dermatology,, Philadelphia V.A. Hospital, Philadelphia, PA, 3Department of Medicine, Temple University School of Medicine, Philadelphia, PA, 4Department of Dermatology, Philadelphia V.A. Hospital, Philadelphia, PA, 5Department of Dermatology, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, 6Department of Dermatology, Veteran Affairs Medical Center, Philadelphia, PA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Apoptosis, cutaneous lupus, inflammatory cytokines and microparticles

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Cutaneous lupus erythematosus (CLE) refers to variants of lupus erythematosus (LE) with exclusively or predominantly skin manifestations. CLE is associated with accumulation of autoantibodies and infiltration of inflammatory cells in the skin. The underlying trigger for autoimmunity in CLE has not been definitively identified. Apoptosis, which generates apoptotic bodies and apoptotic blebs, the latter also known as membrane microvesicles (MVs), have been proposed to play a central role in autoimmune diseases, particularly when normal mechanisms for clearance of apoptotic cells, bodies and MVs are impaired. We and others have shown that apoptotic MVs exert pro-inflammatory properties. The role of MVs in CLE has not been studied. In addition, tobacco smoking has emerged as a risk factor for CLE, particularly severe and refractory forms, but the underlying mechanisms are unclear. Our recent publications showed that exposure of human monocyte/macrophages to tobacco smoke extract (TSE) provokes apoptosis and the release of potent, biologically active MVs. LL-37 is a cathelicidin antimicrobial peptide with proinflammatory properties that has been described as a soluble molecule or released with neutrophil extracellular traps (NETs), and is involved in autoimmune diseases. In the current study, we hypothesized a role for MVs in CLE in the transport of LL-37, a cathelicidin antimicrobial peptide with proinflammatory properties. 

Methods:

Blood and skin biopsy samples were collected from CLE patients and healthy control subjects. Platelet-free plasma was isolated by sequential centrifugation. Freshly harvested skin samples were rinsed with PBS, and then minced into small pieces in DMEM for later analysis of MVs. Cultured human HL-60 neutrophils, THP-1 monocytes, and peripheral blood monocytic ce lls (PBMCs) were treated without or with tobacco smoke extract (TSE), and then the cells were examined by fluorescent microscopy, and the cells and supernatants were analyzed with flow cytometry. 

Results:

We found that skin lesions of CLE patients contain MVs that carry LL-37. Flow cytometry analysis using cell-specific markers revealed that LL-37-positive MVs in CLE skin lesions are largely of neutrophil origin. In plasma, we found increased concentrations of circulating total- and LL-37-positive MVs in CLE patients, compared to healthy controls. Most importantly, we found that MVs isolated from the plasma of CLE patients can stimulate TNFα release from PBMCs. In addition, exposure of human HL-60 neutrophils, THP-1 monocytes, or PBMCs isolated from healthy volunteers to TSE significantly increased their production of total- and LL-37-positive MVs. Treatment of PBMCs or THP-1 monocytes with TSE induced the redistribution of LL-37 to the cell surface, a prerequisite for export of this molecule on membrane MVs.

Conclusion:

Our studies indicate for the first time that extracellular LL-37 can be carried by MVs.  These LL-37-positive MVs are present in skin lesions and the circulation of patients with CLE. Microvesicles in CLE can stimulate cytokine release from nearby inflammatory cells and may thereby contribute to cutaneous inflammation.


Disclosure:

M. L. Liu,
None;

M. Bashir,
None;

M. Sharma,
None;

H. Xu,
None;

K. Williams,
None;

C. O. Anyanwu,
None;

J. Okawa,
None;

V. P. Werth,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/novel-proinflammatory-microvesicles-that-carry-ll-37-in-patients-with-cutaneous-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology